首页AMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
收入 | 41.60万 | -99.59% |
经营支出 | 1782.80万 | -63.41% |
净收入 | -7270.40万 | -447.98% |
净利润率 | -1.75万 | -85,981.67% |
每股收益 | -1.07 | -456.67% |
息税折旧摊销前利润 | -7544.00万 | -496.59% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 2.34亿 | -33.98% |
总资产 | 2.51亿 | -46.27% |
负债总额 | 5451.00万 | 13.13% |
权益总额 | 1.96亿 | — |
发行在外的股份 | 6854.79万 | — |
市净率 | 1.81 | — |
资产回报率 | -64.90% | — |
资本回报率 | -81.67% | — |
现金流
现金净变动
| (USD) | 2024年9月info | 年同比变化 |
|---|---|---|
净收入 | -7270.40万 | -447.98% |
来自运营的现金 | -4157.00万 | -704.22% |
投资现金 | 3881.60万 | 135.91% |
融资现金 | 8.00万 | -91.00% |
现金净变动 | -243.80万 | 97.83% |
自由现金流 | -8617.51万 | -1,426.30% |
简介
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
成立时间
2013
员工数量
384
